{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:48:45Z","timestamp":1777495725045,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1124\/jpet.112.198895","type":"journal-article","created":{"date-parts":[[2012,11,30]],"date-time":"2012-11-30T05:36:02Z","timestamp":1354253762000},"page":"501-510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["In Vivo Occupancy of Dopamine D3 Receptors by Antagonists Produces Neurochemical and Behavioral Effects of Potential Relevance to Attention-Deficit\u2013Hyperactivity Disorder"],"prefix":"10.1016","volume":"344","author":[{"given":"V.","family":"Barth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.B.","family":"Need","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.T.","family":"Tzavara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Giros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Overshiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.D.","family":"Gleason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.G.","family":"Nomikos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Witkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.112.198895_bib1","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1016\/j.lfs.2005.11.031","article-title":"Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer","volume":"78","author":"Barth","year":"2006","journal-title":"Life Sci"},{"key":"10.1124\/jpet.112.198895_bib2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ajmg.b.30710","article-title":"DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents","volume":"147B","author":"Bombin","year":"2008","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1124\/jpet.112.198895_bib3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.euroneuro.2009.11.012","article-title":"(+)-UH 232, a partial agonist of the D3 dopamine receptors, attenuates cognitive effects of angiotensin IV and des-Phe(6)-angiotensin IV in rats","volume":"20","author":"Braszko","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1124\/jpet.112.198895_bib4","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/0024-3205(85)90219-X","article-title":"Measurement of acetylcholine and choline in brain by HPLC with electrochemical detection","volume":"37","author":"Bymaster","year":"1985","journal-title":"Life Sci"},{"key":"10.1124\/jpet.112.198895_bib5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.lfs.2005.04.075","article-title":"Use of LC\/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples","volume":"78","author":"Chernet","year":"2005","journal-title":"Life Sci"},{"key":"10.1124\/jpet.112.198895_bib6","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1126\/science.1197410","article-title":"Structure of the human dopamine D3 receptor in complex with a D2\/D3 selective antagonist","volume":"330","author":"Chien","year":"2010","journal-title":"Science"},{"key":"10.1124\/jpet.112.198895_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/jpet.105.085472","article-title":"Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior","volume":"314","author":"Collins","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.198895_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/7854_2011_121","article-title":"Rodent models of ADHD","volume":"9","author":"Fan","year":"2012","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1124\/jpet.112.198895_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/BF00212840","article-title":"Stereoselective binding of 11C-raclopride in living human brain-a search for extrastriatal central D2-dopamine receptors by PET","volume":"94","author":"Farde","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.112.198895_bib9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/jpet.102.047241","article-title":"Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization","volume":"305","author":"Fox","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.198895_bib10","first-page":"261","article-title":"Annu Rev","volume":"43","author":"Gainetdinov","year":"2003","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/jpet.112.198895_bib11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/syn.21535","article-title":"Affinity and selectivity of [\u00b9\u00b9C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo","volume":"66","author":"Gallezot","year":"2012","journal-title":"Synapse"},{"key":"10.1124\/jpet.112.198895_bib12","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/379606a0","article-title":"Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter","volume":"379","author":"Giros","year":"1996","journal-title":"Nature"},{"key":"10.1124\/jpet.112.198895_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1741-7007-2-22","article-title":"Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson\u2019s disease, and downregulates the dopamine transporter via the D3 receptor","volume":"2","author":"Joyce","year":"2004","journal-title":"BMC Biol"},{"key":"10.1124\/jpet.112.198895_bib41","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0006-3223(98)00204-2","article-title":"Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy","volume":"45","author":"Kapur","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.112.198895_bib14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/syn.20867","article-title":"In vitro and in vivo comparison of [\u00b3H](+)-PHNO and [\u00b3H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: a method to distinguish dopamine D\u2083 from D\u2082 receptor sites","volume":"65","author":"Kiss","year":"2011","journal-title":"Synapse"},{"key":"10.1124\/jpet.112.198895_bib15","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/sj.npp.1300114","article-title":"Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex","volume":"28","author":"Lacroix","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.112.198895_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-004-2096-z","article-title":"Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats","volume":"179","author":"Laszy","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.112.198895_bib17","first-page":"36","article-title":"[Influence of dopamine agonist pramipexole (mirapex) on tremor, cognitive and affective impairment in patients with Parkinson\u2019s disease]","volume":"109","author":"Levin","year":"2009","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"10.1124\/jpet.112.198895_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0031-6997(24)01327-9","article-title":"The D3 dopamine receptor: neurobiology and potential clinical relevance","volume":"49","author":"Levant","year":"1997","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.112.198895_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pscychresns.2006.12.012","article-title":"Dopamine D2\/D3 receptor binding in the anterior cingulate cortex and executive functioning","volume":"156","author":"Lumme","year":"2007","journal-title":"Psychiatry Res"},{"key":"10.1124\/jpet.112.198895_bib20","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/npp.2010.50","article-title":"The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro","volume":"35","author":"McCormick","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.112.198895_bib21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.phrs.2010.02.003","article-title":"Enhanced cognitive performance of dopamine D3 receptor \u201cknock-out\u201d mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid\/endovanilloid systems","volume":"61","author":"Micale","year":"2010","journal-title":"Pharmacol Res"},{"key":"10.1124\/jpet.112.198895_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157488906778773634","article-title":"Selective dopamine D3 receptor antagonists: a review 2001-2005","volume":"1","author":"Micheli","year":"2006","journal-title":"Recent Patents CNS Drug Discov"},{"key":"10.1124\/jpet.112.198895_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2515\/therapie:2008041","article-title":"Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138","volume":"63","author":"Millan","year":"2008","journal-title":"Therapie"},{"key":"10.1124\/jpet.112.198895_bib42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes","volume":"303","author":"Millan","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.198895_bib24","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.lfs.2007.09.005","article-title":"In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC\/MS\/MS and the administration of three tracers simultaneously","volume":"81","author":"Need","year":"2007","journal-title":"Life Sci"},{"key":"10.1124\/jpet.112.198895_bib25","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bcp.2012.06.023","article-title":"Medication discovery for addiction: translating the dopamine D3 receptor hypothesis","volume":"84","author":"Newman","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.112.198895_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00001756-200001170-00044","article-title":"Role of dopamine D3 receptors in thermoregulation: a reappraisal","volume":"11","author":"Perachon","year":"2000","journal-title":"Neuroreport"},{"key":"10.1124\/jpet.112.198895_bib27","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1996"},{"key":"10.1124\/jpet.112.198895_bib28","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/syn.20658","article-title":"In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice","volume":"63","author":"Rabiner","year":"2009","journal-title":"Synapse"},{"key":"10.1124\/jpet.112.198895_bib29","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/mds.23714","article-title":"Milestones in Parkinson\u2019s disease therapeutics","volume":"26","author":"Rascol","year":"2011","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.112.198895_bib43","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0022-3565(24)39184-0","article-title":"Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A","volume":"294","author":"Reavill","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.198895_bib30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00001756-199501000-00026","article-title":"A functional test identifies dopamine agonists selective for D3 versus D2 receptors","volume":"6","author":"Sautel","year":"1995","journal-title":"Neuroreport"},{"key":"10.1124\/jpet.112.198895_bib31","first-page":"CD005504","article-title":"Levodopa for restless legs syndrome","volume":"16","author":"Scholz","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/jpet.112.198895_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0893-133X(01)00400-6","article-title":"Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat","volume":"26","author":"Shirazi-Southall","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.112.198895_bib33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/347146a0","article-title":"Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics","volume":"347","author":"Sokoloff","year":"1990","journal-title":"Nature"},{"key":"10.1124\/jpet.112.198895_bib34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0091-3057(98)00230-5","article-title":"The dopamine D3\/D2 receptor agonist 7-OH-DPAT induces cognitive impairment in the marmoset","volume":"63","author":"Smith","year":"1999","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.112.198895_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.b.20045","article-title":"Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia","volume":"124B","author":"Szekeres","year":"2004","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1124\/jpet.112.198895_bib36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.mp.4001763","article-title":"Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine","volume":"11","author":"Tzavara","year":"2006","journal-title":"Mol Psychiatry"},{"key":"10.1124\/jpet.112.198895_bib37","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.biopsych.2005.08.019","article-title":"Endocannabinoids activate vanilloid TRPV1 receptors to reduce hyperdopaminergia related hyperactivity: therapeutic implications","volume":"59","author":"Tzavara","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.112.198895_bib44","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s002130000466","article-title":"Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats","volume":"150","author":"Wadenberg","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.112.198895_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF01244979","article-title":"The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity","volume":"94","author":"Waters","year":"1993","journal-title":"J Neural Transm Gen Sect"},{"key":"10.1124\/jpet.112.198895_bib38","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1476-5381.2011.01412.x","article-title":"Animal models to guide clinical drug development in ADHD: lost in translation?","volume":"164","author":"Wickens","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.112.198895_bib39","doi-asserted-by":"crossref","unstructured":"Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Peters S, Shannon HE, Gasior M (2004) Protection against cocaine and methamphetamine overdose toxicity in mice by the dopamine D3\/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol. + -PD 128,907 J Pharmacol Exp Ther 308:957\u2013964.","DOI":"10.1124\/jpet.103.059980"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524185151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524185151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.112.198895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:19:04Z","timestamp":1739985544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524185151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0022356524185151"],"URL":"https:\/\/doi.org\/10.1124\/jpet.112.198895","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vivo Occupancy of Dopamine D3 Receptors by Antagonists Produces Neurochemical and Behavioral Effects of Potential Relevance to Attention-Deficit\u2013Hyperactivity Disorder","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.112.198895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}